OCEANIC-STROKE Revives Optimism for Factor XI Inhibitors
Davide Capodanno, Professor of Cardiology at University of Catania, editor-in-Chief of EuroIntervention, shared on X:
”Finally, some good news for Factor XI inhibitors, a class of anticoagulants that was starting to look genuinely unfortunate—full of promising hypotheses and remarkably short on outcomes. OCEANIC-STROKE is positive, according to a press release issued today, and notably soon after the announcement that LIBREXIA-ACS had been stopped for futility. Just as the last nail seemed ready to seal the coffin, the lid reopened and out came asundexian—the same agent for which, after OCEANIC-AF, we had essentially already recited the de profundis.
According to the press release, OCEANIC-STROKE met its primary efficacy and safety endpoints: asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared with placebo, on top of antiplatelet therapy, in patients after a non-cardioembolic ischemic stroke or high-risk TIA. There was no increase in ISTH major bleeding with asundexian.
So the same drug that failed against apixaban in cardioembolic stroke succeeds against placebo in non-cardioembolic stroke (on a background of antiplatelet therapy), highlighting the fundamentally different nature of thrombi in these two conditions.
It is also notable—judging from this sequence of press releases—that factor XI inhibition currently appears more effective in ischemic stroke (asundexian) than in acute coronary syndromes (milvexian), a scenario almost inverted compared with expectations only a few weeks ago. And several shots remain in the chamber (LIBREXIA-STROKE with milvexian; LILAC, ASTER and MAGNOLIA with the monoclonal antibody abelacimab).
OCEANIC-STROKE press release here.
LIBREXIA-ACS press release here.

Find more posts on Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants